DS
MRTX

David Shaw’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

David Shaw’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,000
Closed -$7.33M – 6087
2021
Q4 		$7.33M Hold
50,000
– – 0.01% 1979
2021
Q3 		$8.85M Hold
50,000
– – 0.01% 1608
2021
Q2 		$8.08M Hold
50,000
– – 0.01% 1676
2021
Q1 		$8.56M Sell
50,000
-30,200
-38% -$5.98M 0.01% 1464
2020
Q4 		$17.6M Buy
80,200
+20,000
+33% +$4.32M 0.02% 1025
2020
Q3 		$10M Buy
60,200
+10,000
+20% +$1.37M 0.01% 1247
2020
Q2 		$5.73M Buy
50,200
+10,000
+25% +$970K 0.01% 1565
2020
Q1 		$3.09M Buy
40,200
+10,000
+33% +$897K ﹤0.01% 1833
2019
Q4 		$3.89M Buy
30,200
+20,000
+196% +$1.93M ﹤0.01% 1929
2019
Q3 		$795K Buy
+10,200
New +$957K ﹤0.01% 2949
2019
Q1 		– Sell
-45,000
Closed -$1.91M – 4007
2018
Q4 		$1.91M Buy
+45,000
New +$1.79M ﹤0.01% 2189

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

David Shaw's MRTX Position: Q1 2024 in Review

David Shaw sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 7,693 shares — an estimated $452K sold.

David Shaw first reported a position in MRTX in Q3 2015 and held it in 25 quarters. The position peaked at $39.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • David Shaw reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • David Shaw sold 7,693 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $452K.
  • David Shaw first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 25 quarters.
  • David Shaw's Mirati Therapeutics, Inc. Common Stock position peaked at $39.6M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.